Company Overview
Company Type: Public Company
Website: sunshinebiopharma.com
Number of Employees: 46
Ticker: SBFM (NasdaqCM)
Year Founded: -


Business Description
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents. It also offers Essential 9, an amino acids capsules; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. Sunshine Biopharma, Inc. is based in Pointe-Claire, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
19.8
Market Capitalization
12.1
TEV/Total Revenue
NM
EBITDA
(12.9)
Total Enterprise Value
(13.8)
TEV/EBITDA
NM
EBIT
(13.0)
Cash & ST Invst.
26.8
P/Diluted EPS Before Extra
NM
Net Income
(37.5)
Total Debt
1.0
Price/Tang BV
0.4x
Capital Expenditure
(0.9)
Total Assets
38.6
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-10-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
(0.08)
(0.08)
(0.30)
(0.01)
(0.30)
Revenue (mm)
8.16
9.11
31.49
62.43
41.08

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
NM

Non-Periodic Estimates

Recommendation
Buy (1.00)
Target Price
4.08
Potential Upside
809.09%


Key Professionals
Name
Title
Slilaty, Steve N.
Chairman, CEO & President
Sebaaly, Camille 
CFO & Secretary
Merzouki, Abderrazzak 
COO & Director
Ferreira, Robert G.
President of Sunshine Bio Investments Inc

Key Board Members
Name
Title
Slilaty, Steve N.
Chairman, CEO & President
Merzouki, Abderrazzak 
COO & Director
Natan, David 
Independent Director
Keller, Andrew Mark
Independent Director
Kiderchah, Rabi 
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
6500 Trans-Canada Highway 4th Floor | Pointe-Claire, QC | H9R 0A5 | Canada
Phone: 514-426-6161   Fax: 514-426-6161

Current and Pending Investors
Armistice Capital LLC, Dutchess Capital, Empery Asset Management, LP, GHS Investments, LLC, Hudson Bay Capital Management LP, Iroquois Capital Management, LLC, RB Capital Partners, Inc., The Bigger Capital Fund, LP

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.45
Market Cap (mm)
11.6
Open
 0.45
Shares Out. (mm)
25.7
Previous Close
 0.45
Float %
74.7%
Change on Day
(0.02)
Shares Sold Short (mm)
0.2
Change % on Day
(4.3)%
Dividend Yield %
-
Day High/Low
 0.48/ 0.41
Diluted EPS Excl. Extra Items
(1.69)
52 wk High/Low
 2.00/ 0.35
P/Diluted EPS Before Extra
NM
Volume (mm)
0.05
Avg 3M Dly Vlm (mm)
0.17
Beta 5Y
(1.04)


 
Delayed Quote** | Last Updated on Oct-11-2023 12:00 AM (GMT-5)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Nora Pharma Inc.
Nora Pharma Inc. operates as a distributor of generic drugs. The company was incorporated in 2017 and is based in Saint-Lambert, Canada. As of October 20, 2022, Nora Pharma Inc. operates as a subsidiary of Sunshine Biopharma, Inc.

United States and Canada
Health Care Distributors
-
-
-
Atlas Pharma Inc.
Atlas Pharma Inc. provides analytical analysis and laboratory services of pharmaceuticals, cosmetics, and natural products. The company was founded in 2012 and is based in Montr√©al, Canada. As of January 1, 2018, Atlas Pharma Inc. operates as a subsidiary of Sunshine Biopharma, Inc.

United States and Canada
Health Care Services
-
-
-
Mountain West Business Solutions, Inc.
As of October 15, 2009, Mountain West Business Solutions, Inc was acquired by Sunshine Biopharma, Inc. in a reverse merger transaction. Mountain West Business Solutions, Inc. does not have significant operations. It intends to provide management consulting with regard to accounting, computer, and general business issues for small and home-office based companies in the Denver, Colorado metropolitan area. The company was founded in 2006 and is based in Littleton, Colorado.

United States and Canada
Research and Consulting Services
-
0.00
0.00
Mountain West Beverage, Inc.

United States and Canada
-
-
-
-
NOX Pharmaceuticals, Inc

United States and Canada
-
-
-
-
Sunshine Biopharma Canada Inc

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-25-2023
Jun-5-2023
Shelf Registration
Target
Sunshine Biopharma, Inc. (NasdaqCM:SBFM)

Armistice Capital, LLC (nka:Armistice Capital LLC)
10.71
May-12-2023
May-16-2023
Private Placement
Target
Sunshine Biopharma, Inc. (NasdaqCM:SBFM)


3.72
Jan-19-2023
-
Buyback
Target
Sunshine Biopharma, Inc. (NasdaqCM:SBFM)


2.00
Oct-20-2022
Oct-20-2022
Merger/Acquisition
Buyer
Nora Pharma Inc.
Sunshine Biopharma, Inc. (NasdaqCM:SBFM)

28.95
May-10-2022
May-20-2022
Shelf Registration
Target
Sunshine Biopharma, Inc. (NasdaqCM:SBFM)

Armistice Capital, LLC (nka:Armistice Capital LLC),Iroquois Capital Management, LLC,The Bigger Capital Fund, LP,Empery Asset Management, LP,Hudson Bay Capital Management LP Seller Funds:Armistice Capital Master Fund Ltd., Iroquois Capital Investment Group, LLC, Iroquois Master Fund Ltd., District 2 Capital Fund LP, Empery Asset Master Ltd, Empery Tax Efficient, Lp, Empery Tax Efficient III, LP, Hudson Bay Master Fund Ltd
28.16
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-22-2023
Delistings
Sunshine Biopharma Receives 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
Aug-10-2023
Buyback Tranche Update
Tranche Update on Sunshine Biopharma, Inc. (NasdaqCM:SBFM)'s Equity Buyback Plan announced on January 19, 2023.
Jun-05-2023
Shelf Registration Filings
Sunshine Biopharma, Inc. has closed its Shelf Registration dated May 25, 2023 in the amount of $10.714286 million.
May-25-2023
Shelf Registration Filings
Sunshine Biopharma, Inc. has filed a Shelf Registration in the amount of $10.714286 million.
May-16-2023
Private Placements
Sunshine Biopharma, Inc. announced that it has received CAD 5 million in funding

M&A Advisors
BCF LLP


Advisors
Most Recent Auditor
B F Borgers CPA, PC
M&A Advisors
BCF LLP
Private Placement Advisors
Aegis Capital Corp.
Public Offering Advisors
Andrew I. Telsey, P.C., B F Borgers CPA, PC, Sichenzia Ross Ference LLP


Most Recent Auditor
B F Borgers CPA PC


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 03:42 AM
SBFM
Sunshine Biopharma Inc 2023_10_05
Reports
15
MarketLine

Sep 30, 2023 06:01 AM
SBFM
Sunshine Biopharma, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
152
MarketLine

Sep 20, 2023 06:01 AM
SBFM
Sunshine Biopharma, Inc.
Reports
41
GlobalData

Sep 14, 2023 11:18 PM
SBFM
Sunshine Biopharma Inc (SBFM.NASD) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
26
GlobalData

Sep 08, 2023 01:30 AM
SBFM
Sunshine Biopharma Inc (SBFM.NASD) - Financial Analysis Review
Reports
120
S&P Global Compustat

Sep 07, 2023 03:29 AM
SBFM
Sunshine Biopharma Inc 2023_09_07
Reports
15
GlobalData

Aug 23, 2023 06:40 AM
SBFM
Sunshine Biopharma Inc (SBFM.NASD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
50
Aegis Capital Corporation
Bouchey, David Michael
Aug 14, 2023 10:50 AM
SBFM
Sunshine Biopharma Beats Our Revenue Expectations - Raising Our Target Price to $3.
EPS Estimates*
5
Aegis Capital Corporation
Bouchey, David Michael
Aug 07, 2023 09:35 AM
SBFM
Sunshine Biopharma - a company with ramping sales and a high-ceiling pipeline.
Initiation of Coverage*
15
Pechala's Reports

Aug 04, 2023 11:00 PM
SBFM
SUNSHINE BIOPHARMA EQUITY WARRANT 15 FEB (SBFMW=US) - SHORT AND LONG TERM FORECASTS FOR ACTIVE TRADERS
Reports
2


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Chamoun, Malek 

3,700,000

14.37

1.7

Aug-25-2023


Armistice Capital LLC

2,194,000

8.52

1.0

Jun-30-2023


Bridgeway Capital Management, LLC

286,100

1.11

0.1

Jun-30-2023


Sebaaly, Camille 

174,465

0.68

0.1

Aug-25-2023


Merzouki, Abderrazzak 

116,720

0.45

0.1

Aug-25-2023


Slilaty Ph.D., Steve N.

116,718

0.45

0.1

Aug-25-2023


Beathard, Robert King

98,080

0.38

0.0

Feb-11-2022


Beathard, Angela R.

98,080

0.38

0.0

Feb-11-2022


Geode Capital Management, LLC

20,179

0.08

0.0

Jun-30-2023


Osaic Wealth, Inc. , Asset Management Arm

11,815

0.05

0.0

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Armistice Capital LLC
2,194,000
2,194,000
Osaic Wealth, Inc. , Asset Management Arm
11,815
5,250
SagePoint Financial Advisors, Inc., Securities Investments
100
100

Top Sellers
Sellers
Common Stock Equivalent Held
Change
BMO Asset Management Corp.
0
(30,000)
Virtu Financial LLC, Asset Management Arm
0
(29,137)
Two Sigma Securities, LLC, Asset Management Arm
0
(25,303)
UBS Asset Management AG
1
(2,406)
Advisory Services Network, LLC
0
(20)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Adva-27a (Future), Alendronate, Amlodipine, Apixaban, Atorvastatin, Azithromycin, BCAA 2:1:1, Candesartan, Candesartan HCTZ, Celecoxib, Cetirizine, Ciprofloxacin, Citalopram, Clindamycin, Clopidogrel, Donepezil, Duloxetine, Dutasteride, Escitalopram, Essential 9, Essential Calcium-Vitamin D, Extreme-Mass, Ezetimibe, Finasteride, Flecainide, Fluconazole, Fluoxetine, Hydroxychloroquine, Iso-Whey, K1.1 (Future), L-Arginine, L-Carnitine, L-Creatine, Lacosamide, Letrozole, Levetiracetam, Mirtazapine, Montelukast, Nora B12-1000, Nora Cal-D 1000, Nora Cal-D 400, Nora Calcium, Nora D-1000, Nora D-400, Nora Senna, Nora Sennosides, NRA K-20, NRA-ASA, NRA-Docusate Sodium, Olanzapine ODT, Olmesartan, Olmesartan HCTZ, Pantoprazole, Paroxetine, Perindopril, Pravastatin, Pregabalin, Quetiapine, Quetiapine XR, Ramipril, Rizatriptan ODT, Rosuvastatin, SBFM-PL4 (Future), Sertraline, Sildenafil, Tadalafil, Telmisartan, Telmisartan HCTZ, Tramadol Acetaminophen, Zolmitriptan, Zopiclone


Upcoming Events
Date/Time
Type
Oct-12-2023 10:00 AM (EST)
Shareholder/Analyst Calls
Nov-10-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-22-2023
-
Sunshine Biopharma, Inc. (NasdaqCM:SBFM)
SEDAR
News Releases
126 KB
Sep-22-2023
-
Sunshine Biopharma, Inc. (NasdaqCM:SBFM)
SEDAR
Material Change Report
126 KB
Sep-22-2023
-
Sunshine Biopharma, Inc. (NasdaqCM:SBFM)
SEDAR
Material Change Report
148 KB
Sep-22-2023
Sep-21-2023
Sunshine Biopharma, Inc. (NasdaqCM:SBFM)
SEC
8-K (8.01)
261 KB
Sep-05-2023
Oct-12-2023
Sunshine Biopharma, Inc. (NasdaqCM:SBFM)
SEC
DEF 14A
84 KB
Aug-28-2023
-
Sunshine Biopharma, Inc. (NasdaqCM:SBFM)
SEDAR
Documents Affecting the Rights of Security Holders
234 KB
Aug-28-2023
-
Sunshine Biopharma, Inc. (NasdaqCM:SBFM)
SEDAR
Documents Affecting the Rights of Security Holders
233 KB
Aug-25-2023
Oct-12-2023
Sunshine Biopharma, Inc. (NasdaqCM:SBFM)
SEC
PRE 14A
84 KB
Aug-14-2023
-
Sunshine Biopharma, Inc. (NasdaqCM:SBFM)
SEDAR
Material Change Report
149 KB
Aug-14-2023
-
Sunshine Biopharma, Inc. (NasdaqCM:SBFM)
SEDAR
Material Change Report
118 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Sebaaly, Camille  (CFO & Secretary)
Nov-30-2022
Common Stock
30,000
31,154
Open Market Acquisition
20.77
Form 4
Sebaaly, Camille  (CFO & Secretary)
Jun-03-2022
Common Stock
25,000
41,484
Open Market Acquisition
20.93
Form 4
Slilaty Ph.D., Steve N. (Chairman, CEO & President)
Feb-18-2022
Series B Preferred stock
(990,000)
(134,653)
Sale to Issuer
New
Form 4
Slilaty Ph.D., Steve N. (Chairman, CEO & President)
Jan-06-2021
Common Stock
100,000
27,203
Other Acquisition
598.19
Form 4
Sebaaly, Camille  (CFO & Secretary)
Jan-06-2021
Common Stock
100,000
27,203
Other Acquisition
513.74
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Slilaty, Steve N.
Chairman, CEO & President
(514) 426-6161
514-426-6161

Merzouki, Abderrazzak 
COO & Director
514-426-6161
514-426-6161

Natan, David 
Independent Director
514-426-6161
514-426-6161

Keller, Andrew Mark
Independent Director
514-426-6161
514-426-6161

Kiderchah, Rabi 
Independent Director
514-426-6161
514-426-6161

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Slilaty, Steve N.
Chairman, CEO & President
(514) 426-6161
514-426-6161

Sebaaly, Camille 
CFO & Secretary
514-426-6161
514-426-6161

Merzouki, Abderrazzak 
COO & Director
514-426-6161
514-426-6161

Ferreira, Robert G.
President of Sunshine Bio Investments Inc
514-426-6161
514-426-6161
-
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT‚ÄôS FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence‚Äôs opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
